The University of Edinburgh
Novel regulators of cancer stem cell biology in acute myeloid leukaemia
Abstract
dc:description.abstractLifelong haematopoiesis depends critically on a small population of bone marrow resident haematopoietic stem cells (HSCs), which possess unique self-renewal capacity and multilineage differentiation potential, ultimately replenishing all blood lineages. In view of these properties, HSC transplantation (HSCT) is an effective treatment for a wide range of bone marrow disorders. However, owing to the rarity of HSCs in adult haematopoiesis, and our inability to effectively expand HSCs in vitro, the clinical need for HSCT vastly exceeds HSC availability. Acute myeloid leukaemia (AML) is an aggressive clonal disorder of haematopoietic stem and progenitor cells (HSPCs), in which the acquisition of mutations by HSPCs results in a block in their myeloid differentiation, and the generation of self-renewing leukaemic stem cells (LSCs). LSCs initiate and propagate the disease, and given that they are treatment-resistant, often fuel disease relapses. The two major challenges in the field of haematopoiesis currently, are therefore to expand HSCs for transplantation, and to identify novel therapeutic targets to eliminate LSCs. In the last decade, epitranscriptomics has developed as a novel layer of regulation of gene expression. RNA N6-methyladenosine (m6A) is the most abundant internal mRNA modification. m6A is installed on mRNA by methyltransferase complexes known as writers and removed by demethylases defined as erasers. The m6A modification is recognised by reader proteins, including those belonging to the YTH domain family (YTHDF1, YTHDF2, YTHDF3, YTHDC1, YTHDC2). While writers and erasers have been implicated in several cancers, including AML, the roles of m6A readers in normal and malignant haematopoiesis remains unexplored. This thesis describes the study of the YTHDF2 m6A reader in normal haematopoiesis and AML. Using the Vav-iCre system to conditionally delete Ythdf2 from the haematopoietic system of mice, we observed a significant increase in the number of haematopoietic stem and progenitor cells (HSPCs) compared to controls. In primary and secondary long-term competitive transplantation assays, Ythdf2-deficient HSCs reconstituted multilineage haematopoiesis and showed an increased capacity to rapidly repopulate the myeloid lineage. Furthermore, bone marrow analysis 4 months after transplantation revealed an increased contribution of Ythdf2-deficient cells to the HSPC compartments of transplanted mice compared to controls. To study the role of Ythdf2 in AML, we compared the ability of Ythdf2-deficient and control pre-LSCs to generate leukaemia in a murine retroviral AML model. We showed that constitutive (Vav-iCre) and inducible (Mx1-Cre) genetic deletion of Ythdf2 severely compromises the development and propagation of leukaemia driven by a range of oncogenes, including Meis1/Hoxa9, Mll-AF9, PML-RARA and MOZ-TIF2. Mechanistically, we showed that loss of Ythdf2 inhibits degradation of multiple m6A-modified transcripts, including Tnfrsf2, whose upregulation sensitizes Ythdf2-deficient LSCs to TNFinduced apoptosis. In summary, we demonstrated that inhibition of Ythdf2 specifically compromises LSC development and propagation, but simultaneously expands HSCs and enhances their myeloid reconstitution upon transplantation. We therefore propose YTHDF2 as a unique therapeutic target whose inhibition selectively targets LSCs while promoting HSC expansion.
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2020
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Paris, Jasmin
- Advisors dc:contributor.advisor
-
- Kranc, Kamil
- Dzierzak, Elaine
Subjects
dc:subject × 5Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- http://dx.doi.org/10.7488/era/198